Tucidinostat

Generic Name: Tucidinostat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₉FN_₄O_₂

CAS Number: 1616493-44-7

Unique Ingredient Identifier: 87CIC980Y0

Indication: Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma (HCC)

Interventions: Drug: Chidamide
Drug: Regorafenib

First Posted Date: 2023-03-16

Last Posted Date: 2024-02-23

Lead Sponsor: Great Novel Therapeutics Biotech & Medicals Corporation

Target Recruit Count: 46

Registration Number: NCT05770882

Locations: 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳
Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
🇨🇳
China Medical University Hospital, Taichung, Taiwan

and more 2 locations

Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer
Chemotherapy Effect

Interventions: Drug: Chidamide

First Posted Date: 2023-02-28

Last Posted Date: 2023-02-28

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT05747313

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing, Beijing, China

Chidamide in Patients With Recurrent and Refractory Diffuse Large b

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Chidamide
Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2023-01-19

Last Posted Date: 2023-01-19

Lead Sponsor: Second Affiliated Hospital of Soochow University

Target Recruit Count: 169

Registration Number: NCT05690191

Locations: 🇨🇳
Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT

Phase 1

Recruiting

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Chidamide

First Posted Date: 2023-01-12

Last Posted Date: 2023-01-12

Lead Sponsor: Sichuan University

Target Recruit Count: 77

Registration Number: NCT05682755

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

Phase 3

Conditions: Peripheral T-cell Lymphoma Targeted Therapy

Interventions: Drug: Azacitidine
Drug: Cyclophosphamide
Drug: Chidamide
Drug: Epirubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2023-01-10

Last Posted Date: 2023-01-10

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 200

Registration Number: NCT05678933

Locations: 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Phase 2

Recruiting

Conditions: HR+/HER2- Breast Cancer

Interventions: Drug: Tucidinostat
Drug: nab-paclitaxel

First Posted Date: 2022-12-01

Last Posted Date: 2023-02-21

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 90

Registration Number: NCT05633914

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

Phase 1

Not yet recruiting

Conditions: HR+/HER2- Advanced Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Chidamide

First Posted Date: 2022-10-19

Last Posted Date: 2022-10-19

Lead Sponsor: Beijing 302 Hospital

Target Recruit Count: 30

Registration Number: NCT05586841

Locations: 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China

Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Phase 2

Recruiting

Conditions: Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Interventions: Drug: Chidamide combined with CHOP
Drug: Chidamide

First Posted Date: 2022-10-10

Last Posted Date: 2022-10-10

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 47

Registration Number: NCT05572983

Locations: 🇨🇳
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong, China

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Phase 2

Recruiting

Conditions: Acute Monocytic Leukemia
Newly Diagnosed

Interventions: Drug: Chidamide
Drug: Azacitidine
Drug: Venetoclax

First Posted Date: 2022-10-04

Last Posted Date: 2024-11-19

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 92

Registration Number: NCT05566054

Locations: 🇨🇳
The First Affliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Phase 1

Recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Azacitidine Injection
Drug: Tucidinostat
Drug: Camrelizumab
Drug: Linperlisib
Drug: SHR2554
Drug: Apatinib
Drug: Dasatinib

First Posted Date: 2022-09-29

Last Posted Date: 2022-11-09

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 116

Registration Number: NCT05559008

Locations: 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy